{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:11:00Z","timestamp":1777695060188,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.vaccine.2013.03.006","type":"journal-article","created":{"date-parts":[[2013,3,18]],"date-time":"2013-03-18T09:29:43Z","timestamp":1363598983000},"page":"2372-2380","source":"Crossref","is-referenced-by-count":31,"title":["Estimating the long-term effects of HPV vaccination in Germany"],"prefix":"10.1016","volume":"31","author":[{"given":"J.","family":"Horn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Damm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.E.","family":"Kretzschmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Deler\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.T.","family":"Mikolajczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2013.03.006_bib0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"issue":"12","key":"10.1016\/j.vaccine.2013.03.006_bib0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.vaccine.2013.03.006_bib0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.vaccine.2013.03.006_bib0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1086\/505982","article-title":"Genital human papillomavirus infection","volume":"43","author":"Dunne","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0025","unstructured":"Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.(GEKID). 2012 cited; Available from: http:\/\/www.gekid.de."},{"key":"10.1016\/j.vaccine.2013.03.006_bib0030","unstructured":"European Medicines Agency. Gardasil, European Public Assessment Report, EPARs for authorised medicinal products for human use; 2006, http:\/\/venice.cineca.org\/EPAR-gardasil.pdf."},{"issue":"9686","key":"10.1016\/j.vaccine.2013.03.006_bib0035","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.vaccine.2013.03.006_bib0040","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"Future II Study Group","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2013.03.006_bib0045","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2013.03.006_bib0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/14712591003601944","article-title":"HPV vaccine: cervarix","volume":"10","author":"Szarewski","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"10.1016\/j.vaccine.2013.03.006_bib0055","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malagon","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2013.03.006_bib0060","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2013.03.006_bib0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0266462310000085","article-title":"Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark","volume":"26","author":"Olsen","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"10.1016\/j.vaccine.2013.03.006_bib0070","first-page":"E070405","article-title":"Universal immunisation with human papillomavirus (HPV) vaccine among females aged 12\u201317 recommended in Germany","volume":"12","author":"Delere","year":"2007","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0075","series-title":"Arzneiverordnungsreport 2009","author":"Schwabe","year":"2009"},{"issue":"5","key":"10.1016\/j.vaccine.2013.03.006_bib0080","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2165\/11599470-000000000-00000","article-title":"The cost effectiveness of human papillomavirus vaccines: a systematic review","volume":"72","author":"Seto","year":"2012","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.vaccine.2013.03.006_bib0085","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1055\/s-2007-965530","article-title":"Long-term public health impact of vaccination against cervical cancer in Germany","volume":"67","author":"Schneider","year":"2007","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"2","key":"10.1016\/j.vaccine.2013.03.006_bib0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10389-008-0228-3","article-title":"Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany","volume":"17","author":"Hillemanns","year":"2008","journal-title":"J Publ Health"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0095","doi-asserted-by":"crossref","unstructured":"Sroczynski G, Schnell-Inderst P, M\u00fchlberger N, et al., Entscheidungsanalytische Modellierung zur Evaluation der Langzeit-Effektivit\u00e4t und Kosten-Effektivit\u00e4t des Einsatzes der HPV-DNA-Diagnostik imRahmen der Zervixkarzinomfr\u00fcherkennung in Deutschland.; 2010. Report No.: Bd. 98,","DOI":"10.1055\/s-0030-1266369"},{"issue":"1","key":"10.1016\/j.vaccine.2013.03.006_bib0100","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.mbs.2005.05.004","article-title":"Vaccination against multiple HPV types","volume":"197","author":"Elbasha","year":"2005","journal-title":"Math Biosci"},{"issue":"24","key":"10.1016\/j.vaccine.2013.03.006_bib0105","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1016\/j.vaccine.2009.09.125","article-title":"Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom","volume":"28","author":"Choi","year":"2010","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2013.03.006_bib0110","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1016\/j.vaccine.2009.06.039","article-title":"Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria","volume":"27","author":"Zechmeister","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0115","unstructured":"Tumorregister M\u00fcnchen. 2012 cited; Available from: http:\/\/www.tumorregister-muenchen.de."},{"issue":"2","key":"10.1016\/j.vaccine.2013.03.006_bib0120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jnci\/djr517","article-title":"Re: Epidemiological Study of Anti-HPV16\/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections","volume":"104","author":"Mikolajczyk","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.vaccine.2013.03.006_bib0125","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"issue":"21","key":"10.1016\/j.vaccine.2013.03.006_bib0130","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/jnci\/djq384","article-title":"Epidemiological study of anti-HPV16\/18 seropositivity and subsequent risk of HPV16 and -18 infections","volume":"102","author":"Safaeian","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.vaccine.2013.03.006_bib0135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.virol.2010.07.046","article-title":"Prevalence and stability of antibodies to 37 human papillomavirus types--a population-based longitudinal study","volume":"407","author":"Antonsson","year":"2010","journal-title":"Virology"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2013.03.006_bib0140","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1099\/vir.0.007823-0","article-title":"Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy","volume":"90","author":"Syrjanen","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0145","series-title":"Durchf\u00fchrung einer versichertenbezogenen Untersuchung zur Inanspruchnahme der Fr\u00fcherkennung auf Zervixkarzinom in den Jahren 2002, 2003 und 2004 auf der Basis von Abrechnungsdaten","author":"Kerek-Bodden","year":"2009"},{"issue":"6","key":"10.1016\/j.vaccine.2013.03.006_bib0150","first-page":"523","article-title":"Cervical biopsy-cytology correlation. A College of American Pathologists Q-Probes study of 22 439 correlations in 348 laboratories","volume":"120","author":"Jones","year":"1996","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.vaccine.2013.03.006_bib0155","first-page":"1","article-title":"Evaluation of cervical cytology","author":"McCrory","year":"1999","journal-title":"Evid Rep Technol Assess (Summ)"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0160","series-title":"Gesundheit in Deutschland","author":"Robert Koch-Institut","year":"2006"},{"issue":"4","key":"10.1016\/j.vaccine.2013.03.006_bib0165","first-page":"259","article-title":"The effectiveness and ultilization of screening cytology for cervical cancer in the Federal Republic of Germany (author's transl.)","volume":"41","author":"Schwartz","year":"1981","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"10.1016\/j.vaccine.2013.03.006_bib0170","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1471-2334-9-119","article-title":"Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model","volume":"9","author":"Insinga","year":"2009","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0180","unstructured":"BQS Bundesgesch\u00e4ftsstelle Qualit\u00e4tssicherung. BQS-Bundesauswertung 2008. Gyn\u00e4kologische Operationen. BQS, 2011. Available from: http:\/\/wwwbqs-outcomede\/2008\/ergebnisse\/leistungsbereiche\/gyn\/buaw\/uebasis."},{"issue":"3","key":"10.1016\/j.vaccine.2013.03.006_bib0185","doi-asserted-by":"crossref","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0190","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00112-009-2012-z","article-title":"Erste Erfahrungen zur Akzeptanz der HPV-Impfung. Durchimpfungsrate eines Jahrgangs in einer Gro\u00dfstadt 1 Jahr nach Impfempfehlung durch die STIKO","volume":"102009","author":"Roggendorf","year":"2009","journal-title":"Monatsschr Kinderheilkd"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0195","unstructured":"Wild F. Impfung gegen humane Papillomviren (HPV). Eine Analyse der Verordnungsdaten Privatversicherter. WIP-Diskussionspapier 3\/2011; 2011."},{"issue":"3","key":"10.1016\/j.vaccine.2013.03.006_bib0200","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0205","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/1471-2334-10-360","article-title":"Incidence of anogenital warts in Germany: a population-based cohort study","volume":"10","author":"Kraut","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2013.03.006_bib0210","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1542\/peds.2009-0674","article-title":"Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States","volume":"124","author":"Forhan","year":"2009","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.vaccine.2013.03.006_bib0215","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/jmv.21910","article-title":"Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study","volume":"82","author":"Iftner","year":"2010","journal-title":"J Med Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2013.03.006_bib0220","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jmv.20863","article-title":"Prevalence of human papillomavirus types in women screened by cytology in Germany","volume":"79","author":"Klug","year":"2007","journal-title":"J Med Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2013.03.006_bib0225","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/1097-0215(20001120)89:6<529::AID-IJC11>3.0.CO;2-G","article-title":"Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy","volume":"89","author":"Schneider","year":"2000","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.vaccine.2013.03.006_bib0230","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis","volume":"7","author":"de Sanjose","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0235","unstructured":"Krebsregister Niedersachsen. 2012 cited. Available from: http:\/\/www.krebsregister-niedersachsen.de\/."},{"key":"10.1016\/j.vaccine.2013.03.006_bib0240","unstructured":"Krebsregister Saarland. 2012 cited. Available from: http:\/\/www.krebsregister.saarland.de\/."},{"issue":"5","key":"10.1016\/j.vaccine.2013.03.006_bib0245","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jnci\/djj067","article-title":"Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention","volume":"98","author":"Castellsague","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.vaccine.2013.03.006_bib0250","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-04-0812","article-title":"Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer","volume":"14","author":"Clifford","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9490","key":"10.1016\/j.vaccine.2013.03.006_bib0255","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(05)67069-9","article-title":"Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis","volume":"366","author":"Clifford","year":"2005","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.vaccine.2013.03.006_bib0260","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jnci\/djs395","article-title":"Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis","volume":"104","author":"Van de Velde","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0265","doi-asserted-by":"crossref","first-page":"d5775","DOI":"10.1136\/bmj.d5775","article-title":"Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model","volume":"343","author":"Jit","year":"2011","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.vaccine.2013.03.006_bib0270","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jnci\/djn019","article-title":"Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination","volume":"100","author":"Goldhaber-Fiebert","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"37","key":"10.1016\/j.vaccine.2013.03.006_bib0275","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1016\/j.vaccine.2009.06.043","article-title":"How to screen for cervical cancer after HPV16\/18 vaccination in The Netherlands","volume":"27","author":"Coupe","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2013.03.006_bib0280","first-page":"587","article-title":"Sexual initiation of youths in selected European countries compared with their sexual and contraceptive knowledge","volume":"19","author":"Krauss","year":"2012","journal-title":"AAEM"},{"issue":"46","key":"10.1016\/j.vaccine.2013.03.006_bib0285","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost-effectiveness of male HPV vaccination in the United States","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2013.03.006_bib0290","doi-asserted-by":"crossref","first-page":"e1001147","DOI":"10.1371\/journal.pmed.1001147","article-title":"Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models","volume":"8","author":"Bogaards","year":"2011","journal-title":"PLoS medicine"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0295","doi-asserted-by":"crossref","first-page":"b3884","DOI":"10.1136\/bmj.b3884","article-title":"Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States","volume":"339","author":"Kim","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2013.03.006_bib0300","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.vaccine.2013.03.006_bib0305","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/jir285","article-title":"Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity","volume":"204","author":"Brisson","year":"2011","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1300265X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1300265X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T22:54:15Z","timestamp":1562799255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1300265X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":61,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0264410X1300265X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.03.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}